| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Chief Technology Officer
1 company
Ester Falconer last filed a Form 4 in September 2021, as Chief Technology Officer at ABCL. Ester Falconer's net worth is not public. Form 4 filings only show shares in the companies where this person was an insider, as of the last filing.
At the last filing, the largest reported position was 875,000 shares of ABCL. The ABCL filings lean toward selling, a net 1,000,000 shares.
Ester Falconer has 3 Form 4 filings on record from March 2021 to September 2021, all as Chief Technology Officer at AbCellera Biologics (ABCL), 2021.
The 3 reported transactions were 2 option exercises and 1 open-market sale.
Counted by filing, the open-market trades come to no purchases and 1 sale worth about $25.5M.
The only open-market sale was 1,000,000 shares of ABCL at an average $25.50 on June 9, 2021, about $25.5M. Twelve months later ABCL was down 65%.
Shares as reported in the last Form 4 for each company; the most recent is from September 2021. Values use today's prices. Any trades after the last filing were not reported, so current holdings may differ.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Jun 9, 2021 | ABCL Abcellera Biologics Inc. | Chief Technology Officer | Sell | 1,000,000 | $25.50 | $25,500,000.00 | -100% | -20.5% | -64.8% |